Please try another search
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. Its product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. The company also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. Intervacc AB (publ) was incorporated in 1983 and is based in Hägersten, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Jan-Ingmar Flock | - | 2023 | Independent Director |
Hakan Bjorklund | - | 2023 | Independent Chairperson |
Lisen Bratt Fredricson | - | 2023 | Independent Director |
Camilla Ramfelt McCarthy | - | 2023 | Independent Director |
Lennart Johansson | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review